Single-agent immunotherapy often fails to achieve durable remission in advanced or metastatic malignancies. Combining distinct checkpoint inhibitors or conjugates overcomes primary and adaptive resistance mechanisms.

Inconsistent clinical outcomes across diverse patient populations. Identifying specific biomarkers prevents ineffective treatment administration and optimizes patient selection.